PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-07-12

Date Title Company
12-Jul-2022 Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration Businesswire
12-Jul-2022 Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough Businesswire
12-Jul-2022 Global Stem Cell Partnering Terms and Agreements 2010-2022 - ResearchAndMarkets.com Businesswire
12-Jul-2022 Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering Businesswire
12-Jul-2022 ProBioGen Teams Up with Granite Bio for Cell Line Development and GMP Manufacturing Services ProBioGen
12-Jul-2022 MolPort streamlines access to the global R&D chemical marketplace MolPort
12-Jul-2022 Global NGS Oncology Market to Reach $51.78 Billion by 2032 - ResearchAndMarkets.com Businesswire
12-Jul-2022 OGT significantly expands global reach OGT
12-Jul-2022 AI-powered drug discovery company Healx opens new labs at Chesterford Research Park Healx
12-Jul-2022 TrakCel launches updated cellular orchestration platform OCELLOS 3.0 to cater for ongoing cell and gene therapy sector evolution TrakCel
12-Jul-2022 ProBioGen Teams Up with Granite Bio for Cell Line Development and GMP Manufacturing Services B3C newswire
12-Jul-2022 SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer Businesswire
12-Jul-2022 Ixaka Appoints Karen Miller as Chief Scientific Officer Businesswire
12-Jul-2022 Lysando AG Strengthens Board of Directors by Appointment of Mr. Sang Jung Kim Businesswire
12-Jul-2022 Vaccentis appoints Martin Munte as CEO and strengthens Board Vaccentis
12-Jul-2022 Scottish Medicines Consortium issues interim acceptance to Novartis’ Adakveo®▼ (crizanlizumab) for preventing recurrent vaso-occlusive crises, the first treatment for sickle cell disorder in over 20 years Novartis
12-Jul-2022 Research shows investigational drug fosters nerve repair after injury University of Brimingham
12-Jul-2022 Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Global Newswire
12-Jul-2022 Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors Novo Nordisk
12-Jul-2022 No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study. Novo Nordisk